About Katharine Knobil
Katharine Knobil is a scientific advisor and director at Infinant Health.
Katharine Knobil reports to the SEC as a director or officer of 5 public companies, including Korro Bio (KRRO), Marker Therapeutics (MRKR) and Pliant Therapeutics (PLRX).
Katharine Knobil first appears on SEC filings in 2019.
Experience
This experience comes from Katharine Knobil's profile and from SEC filings. For roles taken from filings, the years are when the filings name Katharine Knobil in the role, so the role may have started earlier or lasted longer.
Infinant Health, Inc. Current
Scientific Advisor and director
Non Executive Director (2025 – Present)
2025 – Present · Sacramento, CA
Makes infant probiotic products for parents and develops a treatment for premature babies.
AI
Altesa BioSciences, Inc. Current
Chief Medical Officer
2025 – Present
KI
Korro Bio, Inc. Current
Non Executive Director (2024 – Present)
Director
2024 – Present · Public company (KRRO)
NT
Nimbus Therapeutics Current
Non Executive Director
2024 – Present
PI
Pliant Therapeutics, Inc. Current
Non Executive Director (2022 – Present)
Director
2022 – Present · Public company (PLRX)
MI
Marker Therapeutics, Inc. Current
Non Executive Director (2021 – Present)
Director
2021 – Present · Public company (MRKR)
AT
Agilent Technologies
Chief Medical Officer
2021 – 2024
AI
Arena Pharmaceuticals Inc.
Non Executive Director (2020 – 2022)
Director
2020 – 2022 · Public company (ARNA)
KI
Kaleido Biosciences, Inc.
Chief Medical Officer
Consultant (2018 – 2021)
2018 – 2021 · Public company (KLDO)
NC
National Health Council
Board Member
2017 – 2018
GS
GSK
Chief Medical Officer
2005 – 2018
Key Colleagues at Startups
The people Katharine Knobil works with at each company, as listed on that company's latest Form D.
Infinant Health, Inc. · Form D, Jun 8, 2026
Laura Stoppel
Director
Michael Johnson
Chief Executive Officer and director
ML
Mike Liang
Director
Amanda Birdsey-Benson
Independent Board Member
RW
Roger Wyse
Director
Patrick Enright
Director